Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis (SCALP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02267135 |
Recruitment Status :
Completed
First Posted : October 17, 2014
Results First Posted : February 28, 2018
Last Update Posted : April 10, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Scalp Psoriasis | Biological: Secukinumab 300 mg Biological: Placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 102 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis |
Actual Study Start Date : | September 29, 2014 |
Actual Primary Completion Date : | December 7, 2015 |
Actual Study Completion Date : | December 7, 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: Secukinumab
Eligible patients will receive secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 20 inclusive
|
Biological: Secukinumab 300 mg
Secukinumab 300 mg will be provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab will consist of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 20 inclusive. In order to maintain the blinding, patients will receive additional placebo injections at Weeks 13, 14 and 15. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur of days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
Other Name: AIN457 300 mg |
Placebo Comparator: Placebo
Eligible patients will receive placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8. Prior to taking the Week 12 dose, the patient will be assessed for response to treatment using the Psoriasis Scalp Severity Index (PSSI). If the subject is a responder, the subject will continue on placebo dosing weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20. Subjects who are not responders will be switched to treatment with secukinumab 300 mg and will dose once weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20.
|
Biological: Placebo
Placebo will be provided in 1 mL prefilled syringe. Each placebo dose will consist of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3 and 4), then after four weeks at Week 8. At Week 12, PSSI responders will continue on placebo and receive their injections once weekly for five weeks (Weeks 12, 13, 14, 15 and 16), then followed by dosing after four weeks at Week 20. PSSI non-responders will be switched to receive 300 mg secukinumab at Weeks 12, 13, 14, 15 and 16, then after four weeks at Week 20. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home. |
- Psoriasis Scalp Severity Index 90 (PSSI 90) [ Time Frame: 12 weeks ]
PSSI 90 response (yes) at Week 12; PSSI 90 response means at least a 90% improvement in scalp psoriasis
Percentage of participants with Psoriasis Scalp Severity Index 90 (PSSI 90) response of "yes"
- Secondary: Investigator's Global Assessment Model 2011 (IGA Mod 2011) Score of 0 or 1 (Scalp Only) [ Time Frame: 12 weeks ]IGA mod 2011 score of 0 or 1 (scalp only) response at Week 12 (non-responder imputation); IGA mod 2011 score of 0 means no sign of scalp psoriasis, and IGA score of 1 means almost no scalp psoriasis
- Change From Baseline in PSSI Score [ Time Frame: 12 weeks ]Change from baseline in Psoriasis Scalp Severity Index (PSSI) score. PSSI score ranges from 0-72 with 72 being severe
- Psoriasis Scalp Severity Index 75 (PSSI 75) Response [ Time Frame: 12 weeks ]PSSI 75 response (yes) at Week 12 (non-responder imputation); PSSI 75 response means at least a 75% improvement in scalp psoriasis
- Psoriasis Scalp Severity Index 100 (PSSI 100) Response [ Time Frame: 12 weeks ]PSSI 100 response (yes) at Week 12 (non-responder imputation); PSSI 100 response means no sign of scalp psoriasis
- Time to 50% Reduction in PSSI Score up to Week 12 [ Time Frame: 12 weeks ]
Time to 50% reduction in PSSI score up to week 12 was estimated for drug arm
The median time to reduction was not estimable for placebo because a 50% reduction in PSSI score was not achieved by enough participants receiving placebo
- Psoriasis Area and Severity Index 75 (PASI 75) [ Time Frame: 12 weeks ]PASI 75 response (yes) at Week 12 (non-responder imputation); PASI 75 response means at least a 75% improvement in body psoriasis
- Psoriasis Area and Severity Index 90 (PASI 90) [ Time Frame: 12 weeks ]PASI 90 response (yes) at Week 12 (non-responder imputation); PASI 90 response means at least a 90% improvement in body psoriasis
- Psoriasis Area and Severity Index 100 (PASI 100) [ Time Frame: 12 weeks ]PASI 100 response (yes) at Week 12 (non-responder imputation); PASI 100 response means no sign of body psoriasis
- Investigator's Global Assessment Model 2011 (GA Mod 2011) Score of 0 or 1 (Entire Body Including Scalp) [ Time Frame: 12 weeks ]IGA mod 2011 score of 0 or 1 (entire body including scalp); IGA mod 2011 score of 0 means no sign of psoriasis, and IGA mod 2011 score of 1 means almost no psoriasis
- Change From Baseline in Subject Assessment of Pain [ Time Frame: 12 weeks ]
Change from baseline in the Subject Assessment of Pain
Scale of 0-10 with 10 being the most painful
- Change From Baseline in Subject Assessment of Itching [ Time Frame: 12 weeks ]
Change from baseline in the Subject Assessment of Itching
Scale of 0-10 with 10 being the most itchy
- Change From Baseline in Subject Assessment of Scaling (Scalp Only) [ Time Frame: 12 weeks ]
Change from baseline in the Subject Assessment of Scaling (scalp only)
Scale of 0-10 with 10 being the most scaling

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Chronic scalp psoriasis for at least the previous six months
- Moderate to severe scalp psoriasis as defined by a PSSI score of ≥12 and 30% or higher of scalp surface area affected
- Must be candidates for systemic therapy, which means having scalp psoriasis inadequately controlled by topical treatments (corticosteroids), and/or phototherapy, and/or previous systemic therapy.
Exclusion Criteria:
- Forms of psoriasis other than chronic plaque
- Drug-induced psoriasis (e.g., new onset or current exacerbation from β-blockers, calcium channel inhibitors)
- Ongoing use of prohibited treatments (e.g., topical or systemic corticosteroids, UV therapy)
- Prior exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL17A or IL-17RA receptors
- Use of other investigational drugs within 30 days prior to study entry, or within a period of 5 half-lives of the investigational treatment, whichever is longer
- Active, ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of secukinumab
- Active system infections (with the exception of the common cold) during the two weeks prior to starting study treatment
- Other protocol-defined inclusion/exclusion criteria may apply

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02267135
United States, California | |
Novartis Investigative Site | |
Sacramento, California, United States, 95819 | |
United States, Colorado | |
Novartis Investigative Site | |
Aurora, Colorado, United States, 80045 | |
United States, Connecticut | |
Novartis Investigative Site | |
Trumbull, Connecticut, United States, 06611 | |
United States, Maryland | |
Novartis Investigative Site | |
Rockville, Maryland, United States, 20850 | |
United States, Massachusetts | |
Novartis Investigative Site | |
Andover, Massachusetts, United States, 01810 | |
Novartis Investigative Site | |
Boston, Massachusetts, United States, 02114 | |
United States, Michigan | |
Novartis Investigative Site | |
Troy, Michigan, United States, 48084 | |
United States, New Jersey | |
Novartis Investigative Site | |
East Windsor, New Jersey, United States, 08520 | |
United States, New York | |
Novartis Investigative Site | |
New York, New York, United States, 10025 | |
Novartis Investigative Site | |
New York, New York, United States, 10075 | |
United States, North Carolina | |
Novartis Investigative Site | |
Winston-Salem, North Carolina, United States, 27157 | |
United States, Ohio | |
Novartis Investigative Site | |
Gahanna, Ohio, United States, 43230 | |
United States, Pennsylvania | |
Novartis Investigative Site | |
Hershey, Pennsylvania, United States, 17033 | |
Novartis Investigative Site | |
Pittsburgh, Pennsylvania, United States, 15213-3403 | |
United States, Texas | |
Novartis Investigative Site | |
Arlington, Texas, United States, 76011 | |
United States, Utah | |
Novartis Investigative Site | |
Salt Lake City, Utah, United States, 84132 | |
Novartis Investigative Site | |
West Jordan, Utah, United States, 84088 |
Study Director: | Novartis Pharmaceuticals | Novartis |
Additional Information:
Responsible Party: | Novartis Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT02267135 History of Changes |
Other Study ID Numbers: |
CAIN457AUS01 |
First Posted: | October 17, 2014 Key Record Dates |
Results First Posted: | February 28, 2018 |
Last Update Posted: | April 10, 2019 |
Last Verified: | March 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com |
scalp psoriasis, plaque psoriasis, secukinumab, AIN457, biologic, monoclonal antibody, psoriasis, AIN457A |
Psoriasis Skin Diseases, Papulosquamous Skin Diseases |
Antibodies, Monoclonal Immunologic Factors Physiological Effects of Drugs |